Aristides Capital’s AnaptysBio ANAB Stock Holding History

Aristides Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,700	Closed	-$168K	–	224
2024 Q4	$168K	Buy	+12,700	New	+$308K	0.03%	265

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristides Capital's ANAB Position: Q1 2025 in Review

Aristides Capital sold out of AnaptysBio (ANAB) in Q1 2025, closing a stake of 12,700 shares — an estimated $168K sold.

Aristides Capital first reported a position in ANAB in Q4 2024 and held it in 1 quarter. The position peaked at $168K in Q4 2024. 153 funds tracked by Wall St. Rank hold ANAB as of Q1 2025.

Aristides Capital reported no remaining AnaptysBio position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 12,700 AnaptysBio shares in Q1 2025, an estimated $168K.
Aristides Capital first reported a position in AnaptysBio in Q4 2024 and held it in 1 quarter.
Aristides Capital's AnaptysBio position peaked at $168K in Q4 2024.
153 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.